Heart Test Laboratories’ (HSCS) Buy Rating Reiterated at Ascendiant Capital Markets

Posted by Tyrone Williams on Sep 27th, 2024

Ascendiant Capital Markets reissued their buy rating on shares of Heart Test Laboratories (NASDAQ:HSCS – Free Report) in a research report sent to investors on Monday, Benzinga reports. They currently have a $15.00 price target on the stock.

Heart Test Laboratories Price Performance

NASDAQ HSCS opened at $4.87 on Monday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 4.02 and a current ratio of 4.49. The business’s fifty day moving average is $3.39 and its 200 day moving average is $6.43. The company has a market capitalization of $3.19 million, a PE ratio of -0.10 and a beta of 3.13. Heart Test Laboratories has a fifty-two week low of $2.36 and a fifty-two week high of $52.00.

About Heart Test Laboratories

(Get Free Report)

Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.